Lymphatic vessel density in the neoplastic progression of Barrett's oesophagus to adenocarcinoma

被引:14
作者
Brundler, MA
Harrison, JA
de Saussure, B
de Perrot, M
Pepper, MS
机构
[1] Univ Geneva, Med Ctr, Dept Clin Pathol, CH-1211 Geneva 4, Switzerland
[2] Univ Geneva, Med Ctr, Dept Morphol, CH-1211 Geneva 4, Switzerland
[3] Birmingham Childrens Hosp, Birmingham B4 6NH, W Midlands, England
[4] Unitas Hosp, NetCare Mol Med Inst, ZA-0140 Pretoria, South Africa
关键词
D O I
10.1136/jcp.2005.028118
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Oesophageal adenocarcinoma is an aggressive neoplasm with poor prognosis as a result of early lymph node metastasis. Aims: To measure lymphatic vessel density (LVD) in the neoplastic progression from Barrett's metaplasia to adenocarcinoma and determine whether LVD can predict the risk of cancer. In addition, to correlate LVD with lymph node metastasis and assess whether LVD could be used as a prognostic indicator for outcome or survival. Methods: LVD and microvascular density (MVD) were assessed after immunohistochemical staining of vessels in Barrett's metaplasia, dysplasia, and adenocarcinoma tissues and were correlated with clinicopathological features. Results: LVD was significantly reduced in adenocarcinoma, being half that seen in normal stomach/oesophagus or metaplasia/dysplasia. LVD did not correlate with tumour grade, stage, or clinical outcome; however, patients who had either lymph node metastasis or invasion of tumour cells into peritumorous lymphatic vessels had a significantly worse overall survival. MVD was also assessed as a prognostic marker; its increase appeared to be linked more with the development of Barrett's metaplasia than adenocarcinoma. Conclusions: The reduction in lymphatic vessel numbers was not useful for determining disease outcome in the patient group studied. It is the entry of tumour cells into pre-existing peritumorous lymphatic vessels that confers a significantly worse overall survival.
引用
收藏
页码:191 / 195
页数:5
相关论文
共 28 条
[1]   Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma [J].
Auvinen, MI ;
Sihvo, EIT ;
Ruohtula, T ;
Salminen, JT ;
Koivistoinen, A ;
Siivola, P ;
Rönnholm, R ;
Rämö, JO ;
Bergman, M ;
Salo, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) :2971-2979
[2]   LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan [J].
Banerji, S ;
Ni, J ;
Wang, SX ;
Clasper, S ;
Su, J ;
Tammi, R ;
Jones, M ;
Jackson, DG .
JOURNAL OF CELL BIOLOGY, 1999, 144 (04) :789-801
[3]   MICROVESSEL QUANTITATION AND PROGNOSIS IN INVASIVE BREAST-CARCINOMA [J].
BOSARI, S ;
LEE, AKC ;
DELELLIS, RA ;
WILEY, BD ;
HEATLEY, GJ ;
SILVERMAN, ML .
HUMAN PATHOLOGY, 1992, 23 (07) :755-761
[4]  
Boyce HW, 2003, J CLIN GASTROENTEROL, V36, pS6, DOI 10.1097/00004836-200305001-00003
[5]  
Clarijs R, 2002, CANCER RES, V62, P7059
[6]   Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis [J].
Corey, KE ;
Schmitz, SM ;
Shaheen, NJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (11) :2390-2394
[7]  
Couvelard A, 2000, J PATHOL, V192, P14
[8]  
Hall N R, 1992, Surg Oncol, V1, P223, DOI 10.1016/0960-7404(92)90068-V
[9]  
HAWK E, 2002, REPORT STOMACH ESOPH
[10]  
HERMANEK P, 1997, ILLUSTRATED GUIDE TN